We have located links that may give you full text access.
PARP Inhibitors: Staying on Target?
Cell Chemical Biology 2016 December 23
Successful phase III trials with poly-ADP-ribose (PARP) inhibitors will have implications for stratified cancer therapy. In this issue of Cell Chemical Biology, Knezevic et al. (2016) demonstrate that the existing collection of PARP inhibitors each display distinctive protein interaction profiles, reaching beyond their intended therapeutic target, with implications for metabolic and other disease.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app